3 New Strong Buy Ratings from Top-Rated Analysts: 12/13/2024

By Jessie Moore, Stock Researcher and Writer
December 12, 2024 3:58 PM UTC
3 New Strong Buy Ratings from Top-Rated Analysts: 12/13/2024

These stocks are cruisin’ … Royal Caribbean Cruises (NYSE: RCL) and Carnival Corp. (NYSE: CCL) both got Strong Buy ratings and price target upgrades this week. In a different sector but similarly hot is Boston Scientific Corp. (NYSE: BSX), which a top-rated analyst believes could see significant upside in the upcoming year. Here’s the story:

1- Royal Caribbean Cruises (NYSE: RCL

Zen Rating: B (BUY)

Analyst/Firm: James Hardiman / Citigroup

Analyst ranking: Top 13% 

Price at writing: $245.52

Price target: $283.00 

  • Maintaining a Strong Buy rating, Citigroup's James Hardiman raised their price target on Royal Caribbean Cruises (NYSE: RCL) by 10.1% from $257 to $283 on 12/11. See more price targets + ratings on RCL here
  • Hardiman told investors that a deep dive into their Consumer Goods (Leisure) sector coverage catalyzed their price target hike.
  • According to the analyst, their recent study of the cruise space indicated good trends that will likely continue into 12/2024, "albeit with pockets of Q/Q weakness" in online traffic. 
  • In spite of a "slight slowdown" following a successful Wave Season earlier this year, consumer interest in cruises remained continuously strong throughout 2023 and into 2024, with indicators indicating stable trends in 2H 2024, Hardiman said. 
  • The analyst expects projections for cruise companies to keep going up and that multiples will rise somewhat as a result of investors chasing the industry's excellent growth characteristics, relative affordability, low valuation, demographic tailwinds, and tariff-free status.

________________________

A message from our sponsors...

Wall Street Takes Notice of a Young Company's Bombshell Discovery! A young company's fortune may have changed virtually overnight... They've uncovered millions of ounces of high-grade, visible gold in North America. This means low extraction costs and with gold forecasts of $3,000/oz, you can see the potential of this find. Wall Street has already taken notice with analysts calling for a 211% upside! Learn more before the market catches on! Reveal this company here.*

* Thanks to our sponsors for keeping this content free.

________________________

2- Carnival Corp. (NYSE: CCL

Zen Rating: B (BUY)

Analyst/Firm: James Hardiman / Citigroup

Analyst ranking: Top 13% 

Price at writing: $26.58

Price target: $30.00 

  • Maintaining a Strong Buy rating, Citigroup's James Hardiman raised their price target on Carnival (NYSE: CCL) by 7.1% from $28 to $30 on 12/11. See more price targets + ratings on CCL here
  • Hardiman told investors that a deep dive into their Consumer Goods (Leisure) sector coverage catalyzed their price target hike.
  • According to the analyst, their recent study of the cruise space indicated good trends that will likely continue into 2024/12, "albeit with pockets of Q/Q weakness" in online traffic. 
  • In spite of a "slight slowdown" following a successful Wave Season earlier this year, consumer interest in cruises remained continuously strong throughout 2023 and into 2024, with indicators indicating stable trends in 2H 2024, Hardiman said. 
  • The analyst expects projections for cruise companies to keep going up and that multiples will rise somewhat as a result of investors chasing the industry's excellent growth characteristics, relative affordability, low valuation, demographic tailwinds, and tariff-free status.

3- Boston Scientific Corp. (NYSE: BSX

Zen Rating: B (Buy)

Analyst/Firm: Joanne Wuensch / Citigroup

Analyst ranking: Top 9% 

Price at writing: $90.56

Price target: $107.00

  • Maintaining a Strong Buy rating, Citigroup's Joanne Wuensch raised their price target on Boston Scientific (NYSE: BSX) by 9.2% from $98 to $107 on 12/11. See more price targets and ratings on BSX here.
  • Wuensch made their price target move on Boston Scientific in a 2025 preview of names in the U.S. Medical Technology sector.
  • The analyst said that they added the name to Citigroup's Focus List because they expect the stock's momentum.
  • Wuensch explained that, for Boston Scientific, "next year's growth drivers should be a retelling of the 2024 story - continued expansion of Farapulse pulsed-field ablation and Watchman left atrial appendage closure adoption and penetration.

What to Do Next? 

Want to get in touch? Email us at news@wallstreetzen.com.

Keep Reading

See All News
Beware Growth Stocks!
Beware Growth Stocks!
Everyone loves growth stocks. But not everyone knows this...
2 months agoSteve Reitmeister
ME
5 Stocks to Watch: Week of 12/16/2024
5 Stocks to Watch: Week of 12/16/2024
Today's list includes Teledyne Technologies (NYSE: TDY), a company with many avenues for continued growth; Procore Technologies Inc. (NYSE: PCOR), which just got a 23% price target increase, Build a Bear Workshop Inc. (NYSE: BBW), a company building success one bespoke teddy bear at a time, M/I Homes (NYSE: MHO), which is also our Stock of the Week, and Boston Scientific Corp. (NYSE: BSX), which is on a run that we think could continue.
2 months agoJessie Moore
BSX
Should You Buy the Dip on Rigel Pharmaceuticals (RIGL)?
Should You Buy the Dip on Rigel Pharmaceuticals (RIGL)?
Not only does RIGL earn an A (Strong Buy) in our Zen Ratings system, but it's our top-rated stock in the entire biotech industry. Keep reading to find out why.
2 months agoMijuško Šibalić
RIGL
3 New Strong Buy Ratings from Top-Rated Analysts: 12/17/2024
3 New Strong Buy Ratings from Top-Rated Analysts: 12/17/2024
Analysts are bullish on PTC Therapeutics (NASDAQ: PTCT) due to exciting products in the pipeline, Imax Corp. (NYSE: IMAX) on news of a robust upcoming movie slate, and Micron Technology (NASDAQ: MU) ahead of earnings. All of these stocks also have A or B Zen Ratings, putting them in a class of stocks that have historically outperformed the market.
2 months agoJessie Moore
PTCT
Hot or Not, Stock Market Edition: 12/19/2024
Hot or Not, Stock Market Edition: 12/19/2024
Walmart (NYSE: WMT) can’t stop, won’t stop. The discount retailer just benefited from a new report from prominent firm Jefferies. Also hot? Pfizer (NYSE: PFE), which expects to hit its 2024 guidance. Not as hot? CVS (NYSE: CVS) continued its cold streak, with a 5.5% loss in a single day, while Broadcom (NASDAQ: AVGO) failed to maintain last week’s momentum.
2 months agoDan Simms
CVS
PFE
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.